G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 3.98 EUR -2.93% Market Closed
Market Cap: 198.4m EUR
Have any thoughts about
Genfit SA?
Write Note

Genfit SA
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genfit SA
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genfit SA
PAR:GNFT
Total Current Liabilities
€36.4m
CAGR 3-Years
6%
CAGR 5-Years
-5%
CAGR 10-Years
10%
Valneva SE
PAR:VLA
Total Current Liabilities
€102.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Total Current Liabilities
€49.9m
CAGR 3-Years
9%
CAGR 5-Years
32%
CAGR 10-Years
32%
Inventiva SA
PAR:IVA
Total Current Liabilities
€48.1m
CAGR 3-Years
48%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Total Current Liabilities
€52.9m
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
19%
OSE Immunotherapeutics SA
PAR:OSE
Total Current Liabilities
€17.4m
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Genfit SA
Glance View

Market Cap
198.3m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
4.93 EUR
Undervaluation 19%
Intrinsic Value
Price
G

See Also

What is Genfit SA's Total Current Liabilities?
Total Current Liabilities
36.4m EUR

Based on the financial report for Jun 30, 2024, Genfit SA's Total Current Liabilities amounts to 36.4m EUR.

What is Genfit SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
10%

Over the last year, the Total Current Liabilities growth was -20%. The average annual Total Current Liabilities growth rates for Genfit SA have been 6% over the past three years , -5% over the past five years , and 10% over the past ten years .

Back to Top